Abstract
22 23
Abstract 24 Sex differences have been observed in multiple facets of cancer epidemiology, treatment and 25 biology, and in most cancers outside the sex organs. Efforts to link these clinical differences to 26 specific molecular features have focused on somatic mutations within the coding regions of the 27 genome. Here, we describe the first pan-cancer analysis of sex differences in whole genomes of 28 1,983 tumours of 28 subtypes from the ICGC Pan-Cancer Analysis of Whole Genomes project. 29 We both confirm the results of exome studies, and also uncover previously undescribed sex 30 differences. These include sex-biases in coding and non-coding cancer drivers, mutation 31 prevalence and strikingly, in mutational signatures related to underlying mutational processes. 32
These results underline the pervasiveness of molecular sex differences and strengthen the call 33 for increased consideration of sex in cancer research. 34
Sex disparities in cancer epidemiology include an increased overall cancer risk in males 35 corresponding with higher incidence in most tumor types, even after adjusting for known risk 36 factors 1, 2 . Cancer mortality is also higher in males, due in part to better survival for female patients 37 in many cancer types, including those of the colon and head & neck 3 . Interestingly, female 38 colorectal cancer patients respond better to surgery 4 and adjuvant chemotherapy, though this is 39 partially due to biases in tumour location and microsatellite instability 5 . Similarly, premenopausal 40 female nasopharyngeal cancer patients have improved survival regardless of tumour stage, 41 radiation or chemotherapy regimen 6 . There is a growing body of evidence for sex differences in 42 cancer genomics [7] [8] [9] [10] [11] [12] [13] , but their molecular origins and clinical implications remain largely elusive. 43
Previous studies have mostly focused on protein coding regions, leaving the vast majority of the 44 genome unexplored. We hypothesized that there are uncharacterized sex differences in the non-45 coding regions of the genome. Using whole genome sequencing data from the Pan-cancer 46
Analysis of Whole Genomes (PCAWG) project 14 , we performed a survey of sex-biased mutations 47 in 1,983 samples (1,213 male, 770 female) from 28 tumour subtypes, excluding those of the sex 48 organs (Supplementary Table 1 ). We also excluded the X and Y chromosomes to focus on 49 autosomal sex differences in cancers affecting both men and women, but there are known to be 50 significant X-chromosome mutational differences between tumours arising in men and women 15 .
51
Our analysis revealed sex differences in both genome-wide phenomena and in specific genes. 52
These sex-biases occur not only at the pan-cancer level across all 1,983 samples, but also in 53 individual tumour subtypes. 54 Sex-biases in driver genes, mutation load and tumour evolution 55 We began by investigating sex differences in driver gene mutation frequencies, focusing on 165 56 coding and nine non-coding mutation events 16 (Supplementary Table 2 ). We used proportions 57 tests to identify candidate sex-biased events with a false discovery rate (FDR) threshold of 10%. 58
These putative sex-biased events were then modeled using logistic regression (LGR) to adjust 59 for tumour subtype, ancestry and age (Online Methods). We found several sex-biased pan-60 cancer driver events, including CTNNB1 which was mutated in 5.0% more male-derived than 61 female-derived tumours (male: 7.6%, female: 2.7%, 95% CI: 2.9-7.0%, prop-test q = 3.6x10 -4 , 62
LGR q = 5.0 x 10 -3
; Figure 1a , left). ALB was also mutated in a larger proportion of male-derived 63 tumours (male: 3.2%, female: 0.54%, 95% CI: 1.4-3.9%, prop-test q = 0.0038, LGR q = 6.5 x 10 -64 3 ) while in contrast, PTCH1 (male: 0.44%, female: 2.0%, 95% CI: 0.38-2.8%, prop-test q = 0.028, 65
LGR q = 0.011) was mutated in more female-derived samples. 66
We also identified tumour subtype-specific sex-biased driver mutations (Figure 1a, right) .
67
Similarly to the pan-cancer driver analysis, we first identified putative sex-biases using proportions 68 tests and a 10% FDR threshold, and followed up with tumour subtype-specific logistic regression 69 models (model descriptions in Supplementary Table 1) . CTNNB1 mutation frequency was sex-70 biased in liver hepatocellular cancer (Liver-HCC), again with more male-derived samples 71 harbouring CTNNB1 mutations: (male: 31%, female: 13%, 95% CI: 8.1-28%, prop-test q = 0.047, 72
LGR q = 8.2x10
-3
, Figure 1a , right). This mirrors our previous finding of sex-biased CTNNB1 73 mutation frequency in liver cancer from TCGA exome sequencing data, with similar effect sizes 74 (male: 33% vs. female: 12%
11
). The largest sex-disparity was in a non-coding driver event in 75 thyroid cancer (Thy-AdenoCA): TERT promoter mutations were observed in 64% of male-derived 76 samples compared with only 11% of female-derived samples (95% CI: 18-89%, prop-test q = 77 6.9x10 -3 , LGR q = 0.074, Figure 1a, , LNR q = 6.5x10 , LNR q= 1.9 x 10 -6 ; Supplementary 98 Table 3 ). These sex-biases remained significant even after adjusting for tumour subtype, ancestry 99 and age in multivariate analysis (Figure 1b, left) , demonstrating robust sex-biases in pan-cancer 100 mutation prevalence across different contexts. 101
We also investigated somatic SNV burden in each of the 23 individual tumour subtypes with at 102 least 15 samples, applying the same statistical approach with tumour subtype-specific models 103 (model descriptions in Supplementary Table 1) . We found sex-biased mutation load in three 104 tumour subtypes (Figure 1b, right) , with higher male coding mutation load in thyroid cancer 105 (difference in location = 0.26 mut/Mbp, 95%CI = 0.12-0.43 mut/Mbp, u-test q = 0.028, LNR q = 106 0.041), and higher male load in hepatocellular cancer and kidney renal cell cancer (Kidney-RCC) 107 in all three contexts (Supplementary Table 3) . We compared the group rank differences of 108 coding and non-coding mutation load between the sexes and found that in renal cell cancer, the 109 differences were similar at 0.40 mut/Mbp for non-coding mutations and 0.37 mut/Mbp for coding 110 mutations. In hepatocellular cancer however, the median sex-difference in non-coding mutation 111 load was higher than the difference in coding mutation load (non-coding difference = 0.84 112 mut/Mbp vs. coding difference = 0.53 mut/Mbp). There is a similar effect in pan-cancer mutation 113 load (non-coding difference = 0.60 mut/Mbp vs coding difference = 0.41 mut/Mbp) suggesting 114 mutation context may play a role in sex-biased SNVs in some tumour subtypes. 115
To determine whether sex-biased mutation load may be associated with sex-biased driver gene 116 mutation frequency, we focused on each driver gene and investigated SNV burden in the relevant 117 tumour subtype. We did not find significant relationships between SNV burden and mutations in 118 PTCH1, ALB, CTNNB1 in pan-cancer analysis, nor was there an association for CTNNB1 119 mutation in hepatocellular cancer. In thyroid cancer however, TERT promoter mutation was 120 associated with increased coding mutation burden (medianTERT-wt = 0.26 mut/Mbp vs medianTERT-121
). We used a linear regression model to determine if the 122 sex-bias in coding mutation load could be explained by TERT mutation frequency and found this 123 was indeed the case (linear regression pTERT = 2.4x10
-5
, psex = 0.37, Figure 1c ). In addition, we 124 examined matched mutation timing data and found that of eleven samples with TERT promoter 125 mutations, nine of these were truncal events, suggesting that an early sex-bias in TERT promoter 126 mutation frequency is associated with sex-biased coding mutation load in this tumour subtype. 127
Indeed, mutations in all sex-biased driver genes were overwhelmingly truncal events. 128
We then asked if these driver mutations might occur at different stages of tumour evolution 129 between men and women, and started with tumour evolution structure. We compared the 130 proportions of polyclonal vs. monoclonal tumours between the sexes and did not find significant 131 sex differences in the proportions of polyclonal tumours bearing mutations in PTCH1, ALB or 132 CTNNB1 for sex-biased pan-cancer drivers, or in TERT promoter-mutated samples in thyroid 133 cancer (Supplementary Figure 1) . We did detect a putative bias in the proportion of polyclonal 134 CTNNB1-mutated samples in hepatocellular cancer (80% of male-derived samples are polyclonal 135
vs. 46% of female-derived samples, 95%CI = -0.019 -0.70, prop-test p = 0.039), and accounted 136 for polyclonality when comparing the timings of the mutations in these driver events. On 137 subsequently examining the frequency of clonal vs. subclonal driver mutation events between the 138 sexes, we found that while there were differences in the proportions of truncal mutations (eg: 139 100% of TERT promoter mutations were truncal events in male-derived vs. 50% truncal events in 140 female-derived thyroid cancer patients), no comparisons were statistically significant. 141
Broadening beyond sex-biased driver mutations, we expanded our clonality analysis to perform 142 a general survey of clonal structure and mutation timing across all tumour subtypes and mutations 143 (Supplementary Table 4 ). We found that female-derived biliary adenocarcinoma (Biliary-144 AdenoCA) tumours were frequently polyclonal, while most male-derived tumours were 145 monoclonal (26% male-derived samples are polyclonal vs. 80% female-derived, 95% CI = 19 -146 88%, prop-test q = 0.063, LGR q = 0.024; Figure 1d ). In addition, we found intriguing evidence 147 suggesting there may be sex-differences in the mutation timing of structural variants in this tumour 148 subtype. Structural variants (SVs) in male-derived samples tended to be truncal events more 149 frequently than in female-derived samples (median male percent truncal SVs = 100% vs. median 150 female = 82%, u-test q = 0.081, LNR q = 0.024; Figure 1e ). Though other comparisons did not 151 reach our statistical significance threshold, we found some interesting trends that may merit future 152 study, including in esophageal cancer (Eso-AdenoCA) where SVs in female-derived samples 153 were more frequently truncal events while SVs in male-derived samples occurred more frequently 154 in subclones (median male percent truncal SVs = 55%, median female = 100%; Supplementary 155
Figure 2), and in medulloblastoma, where insertion-deletions (indels) were more frequently 156 truncal events in female-derived samples than male (median male percent of truncal indels = 157 65%, median female proportion of truncal indels = 70%; Supplementary Figure 3) . Our analysis 158 of sex differences in tumour evolution identified some sex-biased events and also hint at putative 159 sex-biases that should be further explored in future analyses. 160
Sex-biases in genome instability and CNAs

161
Next, we examined percent genome altered (PGA), which provides a summary of copy number 162 aberration (CNA) load. A proxy for genome instability, PGA is a complementary measure of 163 mutation density to somatic SNV burden. While we did not find associations between sex and 164 autosome-wide PGA, we observed sex-biases in the copy number burden for specific 165 chromosomes (Figure 2a) . In pan-cancer analysis, male-derived samples exhibited a slight but 166 significant higher percent chromosome altered for chromosome 7 even after accounting for 167 tumour subtype, ancestry and age using linear regression (median male PGA-7 = 5.4%, median 168 female PGA-7 = 0.37%, difference in location = 0.0037%, 95%CI = 9.4x10 LGR q-value < 10%). These genes were all more 178 frequently gained in male-derived samples than female with a difference in copy number gain 179 frequency reaching ~10% on chromosomes 7 and 8. Genes with male-dominated copy number 180 gains include the oncogenes MYC (male gain frequency = 37% vs. female gain frequency = 28%, 181 95% CI = 5.2-14%, prop-test q = 2.5x10 LGR q = 0.053), mirroring our finding of higher male pan-cancer mutation frequency on the SNV 186 level for this oncogene. We did not find pan-cancer sex-biased copy number losses. 187
We repeated this analysis for every tumour subtype independently and found sex-biased CNAs 188 in renal cell and hepatocellular cancer (Supplementary Tables 6 & 7) . In renal cell cancer, the 189 1,986 sex-biased gains all occurred more frequently in male-derived samples, with differences in 190 frequency up to 35% (Figure 2c) . They spanned across chromosomes 7 and 12, agreeing with 191 our finding of male-dominated genome instability in these chromosomes (Figure 2a,  192 Supplementary Figure 4) . In contrast to the male-dominated gain pan-cancer and renal cell 193 findings, we found higher female frequency of copy number losses in hepatocellular cancer 194 (Figure 2d) . We identified 2,610 genes with higher copy number loss rates in female-derived We found an additional 203 genes on the p-arm of chromosome 8 that were more frequently lost 207 in female-derived samples in biliary cancer (Supplementary Figure 5) . These copy number 208 losses were 50% more common in female-derived samples and affect genes such as DLC1, a 209 known tumour suppressor in hepatocellular cancer that is thought to play a similar role in 210 gallbladder cancer
18
. While we did not identify additional sex-biased CNAs in non-Hodgkin 211 lymphoma, chronic lymphocytic leukemia or melanoma, the sex-biased PGA results suggest 212 these as regions of interest for future work. Thus in addition to sex-biased SNV events, we also 213 identified sex-biased CNAs from this whole genome sequencing data. 214 215 We hypothesized that sex differences in mutation load and tumour evolution characteristics may 216 be driven by varying mutational processes. In addition to single base substitution (SBS) 217 signatures, which have been well annotated and linked to tumour aetiology 19, 20 , we also examined 218 doublet base substitution (DBS) and small insertion-deletion (ID) signatures. Sex differences in a 219 mutational signature could shine insight on molecular differences between the sexes. ) and was also associated with a higher percentage of mutations in these samples (male 231 median percent mutations attributed to SBS1 = 8.4%, female median = 10%, u-test q =0.026, 232 LNR q = 0.021). SBS1 is thought to be caused by deamination of 5-methylcytosine to thymine, 233 resulting in base substitutions. Though it is correlated with age, our multivariate model accounts 234 for this variable and the sex-bias remains even adjusting for age. SBS40 was also detected in a 235 larger proportion of female-derived samples (42% of male-derived vs. 52% of female-derived, χ 2 -236 test q = 1.7x10 -4
Sex biases in mutation signatures
, LNR q = 0.08), though we did not find a difference in the percentage of attributed 237 mutations (u-test q = 0.17). Other sex-biased SBS signatures include SBS16, SBS17a and 238 SBS17b, which were all more frequently detected in male-derived samples, and SBS40, which 239 was more frequent in female-derived samples. These signatures are of unknown aetiology. 240
One ID signature was detected at different rates between the sexes, and two ID signatures had 241 different rates of attributed mutations. ID8 occurred more frequently in male-derived samples 242 (53% of male-derived vs. 47% of female-derived, χ 2 -test q = 0.068, LGR q = 0.018) though there 243 was no difference in the percentage of mutations attributed to either signature. The aetiology 244 underlying ID8 is not known, but this signature is thought to be associated with double strand 245 break repair where ID8-asosciated mutations resemble those related to radiation-induced 246 damage. Conversely, ID1 and ID5 were detected at similar frequencies between the sexes, but 247 had higher percentages of attributed mutations in female-derived samples. Mutations associated 248 with ID1 are thought to result from slippage during DNA replication and are associated with 249 defective DNA mismatch repair, suggesting that while male-and female-derived tumours harbour 250 defective DNA repair at similar rates, it is responsible for a larger proportion of mutations in 251 female-derived tumours. 252
Since mutational processes are disease-specific, we repeated the mutational signatures analysis 253 in each tumour subtype, again by first using univariate techniques to find putatively sex-biased 254 signatures, and then using linear models to adjust for age and ancestry. We identified six sex-255 biased signatures in hepatocellular cancer (Figure 3b, Supplementary Table 8 ). As previously described, SBS1 and ID1 are 267 associated with base deamination and defective DNA mismatch repair. ID3 is associated with 268 tobacco smoke, and ID8 with double-stranded break repair. Taken together, sex-biases in the 269 aetiology underlying the molecular landscape of hepatocellular cancer begin to emerge. In this 270 tumour subtype, spontaneous or enzymatic deamination of 5-methylcytosine to thymine and 271 defective mismatch repair occur more frequently in female patients and are also responsible for 272 more mutations. Conversely, tobacco smoking is more common in male patients though the 273 number of mutations attributed to tobacco smoke is not different between the sexes; this leads to 274 more tobacco-associated male hepatocellular tumours. 275
In B-cell non-Hodgkin lymphoma, we identified a significant difference in the proportion of samples 276 with SBS17b-attributed mutations (Figure 3c, Supplementary Table 8 ). More male-derived 277 samples had mutations associated with this signature of unknown aetiology (57% of male-derived 278 vs. 25% of female-derived, χ 2 -test q = 0.051, LGR q = 6.3x10 -4
). There were also several intriguing 279 sex-differences in mutational signatures that did not meet our significance threshold. For instance, 280 DBS2 accounts for a higher percentage of mutations in male-derived samples (male median 281 percent mutations attributed to DBS2 = 50%, female median = 33%, Supplementary Table 8) . 282 DBS2's association with tobacco smoking suggests that future insight in this signature may 283 provide molecular explanations for the sex-specific associations between smoking and thyroid 284 cancer risk
22
. As the aetiologies of these mutational signatures become better known, we can 285 better approach the causes of molecular sex differences underlying cancer aetiology and 286
progression. In particular, we may be able to discern environmental and lifestyle factors even in 287 the absence of reported data, and connect known risk factors with newly described mutational 288 processes. 289
Finally, to ensure that our findings were not skewed by differences in sequencing quality, we 290 checked for sex-biases in quality control (QC) metrics. These included comparing the coverage,percentage of paired reads mapping to different chromosomes, and overall quality summary of 292 both tumour and normal genomes. We mirrored our main analyses and used u-tests or χ 2 tests 293 and linear modeling to check each QC metric. We did not find sex-biases in any QC metric in pan-294 cancer or tumour subtype analysis after multiple adjustment except in raw somatic mutation 295 calling (SMC) coverage. SMC coverage was higher in male-derived samples in six tumour 296 subtypes including thyroid cancer and esophageal cancer, and was higher in female-derived 297 samples in lung adenocarcinoma and B-cell non-Hodgkin lymphoma (Supplementary Table 9 ).
298
While we do not find sex differences in comparing the SMC coverage pass/fail rates using a 299 recommended minimum of 2.6 gigabases covered, it is prudent to consider sex-biased SMC in 300 relation to our findings. There are also no sex-differences in the proportions of samples passing 301 quality checks for any other QC metric (Supplementary Table 9, Supplementary Figures 6) . 302
Our analysis of whole genome sequencing data from the PCAWG project uncovered sex 303 differences in the largely unexplored non-coding autosomal genome. We found these biases in 304 measures of mutational load, tumour evolution, mutational signatures, and at the gene level. 305
While the majority of our findings describe pan-cancer differences, we have also uncovered an 306 intriguing glimpse into tumour subtype-specific differences. These tumour subtype-specific results 307
are limited by subtype sample size, and limited available annotation restricts the ability to account 308 for confounding variables. It is important to consider these results in context of the multivariable 309 models used, which do not directly capture characteristics such as tobacco smoking history or 310 tumour stage at diagnosis. Future increases in sample size and robust associated annotation will 311 allow for the detection of smaller effects and the control of more confounders. Nevertheless, our 312 analyses of driver genes and copy number alterations suggest functional impacts of genomic sex-313 biases on the transcriptome and tumorigenesis. By using signatures to distinguish between 314 mutations attributed to lifestyle factors such as smoking, we can better describe sex differences 315 related to biological factors such as hormone activity. And despite low tumour subtype-specific 316 sample numbers, our mutation timing and mutational signatures findings at both the pan-cancer 317 and tumour-subtype level hint at underlying mutational processes that may give rise to molecular 318 sex-biases. Combined with our previous work in whole exome sequencing, we present a 319 landscape of sex-biases in cancer genomics and mutational processes (Figure 4 , 320 Supplementary Figure 7) . 321
It is becoming clear that sex differences occur across many mutation classes and the portrait of 322 differences for each tumour subtype is a unique reflection of active mutational processes and 323 tumour evolution. We have performed here the first pan-cancer analysis of sex differences in 324 whole genome sequencing data and catalogued previously undescribed sex-biases. However, 325 increased study of molecular sex differences in future large-scale sequencing efforts is needed 326 to strengthen the findings we present here, to determine why men and women have molecularly 327 different tumours, and to determine how this information can be leveraged to improve patient care. 328 Genome-spanning CNA analysis 517 Consensus copy number data was processed to gain/neutral/loss calls per gene. The number of 518 loss, neutral and gain calls were summed per sex, and assessed using univariate and multivariate 519 techniques. For univariate analysis, proportional differences between the sexes for gains and 520 losses were tested for each gene using proportions tests. After identifying candidate pan-cancer 521 univariately significant genes, multivariate logistic regression was used to adjust ternary CNA data 522 for sex, age, ancestry and tumour-type. The genome-spanning analysis was performed 523 separately for losses and gains for each tumour subtype. 524
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The number of mutations attributed to each SBS, DBS and ID signature per sample was 526 downloaded from Synapse (https://www.synapse.org/#!Synapse:syn8366024). For each 527 signature, we compared the proportion of samples with any mutations attributed to the signatures 528 ("signature-positive") using χ 2 -square tests to identify univariately significant sex-biases. 529
Signatures with putative sex-biases were further analysed using logistic regression. 530
We also compared the proportions of mutations attributed to each signature. The numbers of 531 mutations per signature were divided by total number of mutations for each sample to obtain the 532 proportion of mutations attributed to the signature. Mann-Whitney U-tests were used to compare 533 these proportions. Putative sex-biased signatures were further analysed using linear regression 534 after Box-cox adjustment. 535
Signatures that were not detected in a tumour subtype was omitted from analysis for that tumour 536 subtype. Statistical analyses were performed for each set tumour subtype, but combining all SBS, 537 DBS and ID signatures. 538
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